• ipharmaservices

Biosimilars of Avastin and Herceptin are approved in the United States

Updated: Aug 29, 2019

Mvasi (bevacizumab) biosimilar of Avastin and Kanjinti (trastuzumab) biosimilar of Herceptin were now available in the United States.


Mvasi is approved in the US for

  • Metastatic colorectal cancer (mCRC) in combination

  • Non-squamous non-small cell lung cancer in combination

  • Glioblastoma

  • Metastatic renal cell carcinoma

  • Metastatic cervical cancer


Kanjinti is approved in the US for

  • HER2-over expressing adjuvant and metastatic breast cancer

  • HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma


Mvasi is available at $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial (WAC price). The price is 15% less than the branded product.

Kanjinti is available at $3,697.26 per 420 mg multi-dose vial. The price is 12% less than the branded product.


Amgen has 10 biosimilars, 3 were approved in the United States.


The out-of-pocket cost was significantly lesser than WAC prices.

©2019 by ipharmaservices